Zejing Pharmaceutical announced that the phase II/III clinical trial of the company's self-developed gicaxitinib hydrochloride tablets (formerly known as jacketinib hydrochloride tablets) to treat adolescents and adults aged 12 and above with non-segmental vitiligo was approved by the State Drug Administration. This drug is a class 1 new drug. The company has independent intellectual property rights. It has a significant inhibitory effect on Janus kinase, blocks the JAK-STAT signaling pathway, and improves iron metabolism imbalance. Currently, the drug is undergoing clinical research on a number of immunoinflammatory diseases and fibrosis diseases, and research to treat myelofibrosis has received support from the national “Major New Drug Creation” science and technology project. This approval will not have a significant impact on the company's recent performance, but there are uncertainties due to the long drug development cycle, many approval processes, and large R&D investment. Investors are kindly requested to be aware of the risks.